Latest News and Press Releases

Dublin, Aug. 19, 2024 (GLOBE NEWSWIRE) -- The "mTOR (Mammalian Target of Rapamycin) Inhibitors - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The...

Dublin, April 05, 2024 (GLOBE NEWSWIRE) -- The "FYARRO Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides...

Dublin, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The "mTOR Inhibitors Global Market Report 2024" has been added to ResearchAndMarkets.com's offering. The global market for mTOR inhibitors is witnessing...

Dublin, Sept. 20, 2023 (GLOBE NEWSWIRE) -- The "mTOR Inhibitors Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global mTOR inhibitors market is on a...

Dublin, June 15, 2022 (GLOBE NEWSWIRE) -- The "mTOR Inhibitors Market, by Drug Type, By Indication, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and...

Dublin, June 08, 2022 (GLOBE NEWSWIRE) -- The "Global PARP Inhibitors Cancer Therapy Market, Price, Dosage & Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's...

Wayne, PA, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for...

Wayne, PA, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for...

Wayne, PA, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for...

CAMBRIDGE, Mass., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Cerulean Pharma Inc. (Nasdaq:CERU), a leader in Dynamic Tumor Targeting™, today provided an update on corporate activities during the quarter...